A review of stapled peptides and small molecules to inhibit protein-protein interactions in cancer

Current Medicinal Chemistry

Volumn 23, Issue 27, 2016, Pages 3025-3043

  Iyer, Vidhya V ^a  

^a VIT UNIVERSITY   (India)

Author keywords

Alpha helix; Cancer; Peptidomimetics; Protein protein interactions; Small molecule antagonists; Stapled peptides

Indexed keywords

3 DEAZANEPLANOCIN A; BETA CATENIN; BH3 PROTEIN; ESTROGEN RECEPTOR; GOSSYPOL; INITIATION FACTOR 4E; INITIATION FACTOR 4G; NOTCH RECEPTOR; OBATOCLAX; PEPTIDE; PEPTIDOMIMETIC AGENT; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P110; PROTEIN P53; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SURVIVIN; TRANSCRIPTION FACTOR EZH2; INITIATION FACTOR; METHYLTRANSFERASE; MOLECULAR LIBRARY; PROTEIN BINDING;

ALPHA HELIX; HUMAN; NEOPLASM; NONHUMAN; PROTEIN PROTEIN INTERACTION; REVIEW; CHEMISTRY; DRUG EFFECTS; METABOLISM; MOLECULAR LIBRARY; NEOPLASMS; PATHOLOGY; PHARMACOLOGY; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; THERAPEUTIC USE;

BETA CATENIN; EUKARYOTIC INITIATION FACTORS; HUMANS; METHYLTRANSFERASES; NEOPLASMS; PEPTIDES; PEPTIDOMIMETICS; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES;

EID: 84990946281     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867323666160627103134     Document Type: Review

References (65)

1. Wells, J.A.; McClendon, C.L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature, 2007, 450, 1001-1009.
2. Lau, Y.H.; de Andrade, P.; Wu, Y.; Spring, D.R. Peptide stapling techniques based on different macrocylisation chemistries. Chem. Soc. Rev., 2015, 44, 91 102.
3. Walensky, L.D.; Bird, G.H. Hydrocarbon-stapled peptides: Principles, practice, and progress. J. Med. Chem., 2014, 57, 6275-6288.
4. Cui, H.K.; Zhao, B.; Li, Y.; Guo, Y.; Hu, H.; Liu, L.; Chen, Y.G. Design of stapled alpha-helical peptides to specifically activate Wnt/beta-catenin signaling. Cell Res., 2013, 23, 581-584.
5. Xu, W.; Kimelman, D. Mechanistic insights from structural studies of beta-catenin and its binding partners. J. Cell Sci., 2007, 120, 3337-3344.
6. Kimelman, D.; Xu, W. Beta-catenin destruction complex: Insights and questions from a structural perspective. Oncogene, 2006, 25, 7482-7491.
7. Takahashi-Yanaga, F.; Kahn, M. Targeting Wnt signaling: Can we safely eradicate cancer stem cells? Clin. Cancer Res., 2010, 16(12), 3153-3162.
8. Takada, K.; Zhu, D.; Bird, G.H.; Sukhdeo, K.; Zhao, J.J.; Mani, M.; Lemieux, M.; Carrasco, D. E.; Ryan, J.; Horst, D.; Fulciniti, M.; Munshi, N.C.; Xu, W.; Kung, A.L.; Shivdasani, R.A.; Walensky, L.D.; Carrasco, D.R. Targeted disruption of the BCL9/beta-catenin complex inhibits oncogenic Wnt signaling. Sci. Transl. Med., 2012, 4(148), 1-18.
9. Grossmann, T.N.; Yeh, J.T.H.; Bowman, B.R.; Chu, Q.,; Moellering, R.E.; Verdine, G.L. Inhibition of oncogenic Wnt signaling through direct targeting of beta-catenin. Proc. Natl. Acad. Sci. U S A., 2012, 109(44),17942-47.
10. Koegel, D. Exploiting BH3 Mimetics for Cancer Therapy. In: Mitochondria: The Anti-Cancer Target for the Third Millennium. Neuzil J, Pervaiz S, Fulda S.-Eds. Springer Science + Business Media Dordrecht, 2014, VIII, 382, 39-58.
11. Besbes, S.; Billard, C. First MCL-1 selective BH3 mimetics as potential therapeutics for targeted treatment of cancer. Cell Death Dis., 2015, 6, e1910.
12. Sattler, M.; Liang, H.; Nettesheim, D.; Meadows, R.P.; Harlan, J.E.; Eberstadt, M.; Yoon, H.S.; Shuker, S.B.; Chang, B.S.; Minn, A.J.; Thompson, C.B.; Fesik, S.W. Structure of Bcl-xL-Bak peptide comples: Recognition between regulators of apoptosis. Science, 1997; 275, 983-986.
13. Petros, A.M.; Nettesheim, D.G.; Wang, E.; Olejniczak, E.T.; Meadows, R.P.; Mack, J.; Swift, K.; Matayoshi, E.D.; Zhang, H.; Thompson, C.B.; Fasik, S.W. Rationale for BclxL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies. Protein Sci., 2000, 9(12), 2528-2534.
14. LaBelle, J.L.; Katz, S.G.; Bird, G.H.; Gavathiotis, E.; Stewart, M.L.; Lawrence, C.; Fisher, J.K.; Godes, M.; Pitter, K.; Kung, A.L.; Walensky, L.D. A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers. J. Clin. Invest., 2012, 122(6), 2018-2031.
15. Chen, L.; Willis, S.N.; Smith, B.J.; Fletcher, J.I.;Hinds, M.G.; Colman, P.G.; Day, C.L.; Adams, J.M.; Huang, D.C. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol. Cell, 2005, 17(3), 393-403.
16. Walensky, L.D.; Kung, A.L.; Escher, I.; Malia, T.J.; Barbuto, S.; Wright, R.D.; Wagner, G.; Verdine, G.L.; Korsmeyer, S.J. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science, 2004, 305(5689), 1466-1470.
17. Moerke, N.J.; Aktas, H.; Chen, H.; Cantel, S.; Reibarkh, M.Y.; Fahmy, A.; Gross, J.D.; Degterev, A.; Yuan, J.Y.; Chorev, M.; Halperin, J.A.; Wagner, G. Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell, 2007, 128, 257-267.
18. Mahalingam, P.; Takrouri, K.; Chen, T.; Sahoo, R.; Papadopoulos, E.; Chen, L.; Wagner, G.; Aktas, B.H.; Halperin, J.A.; Chorev, M. Synthesis of rigidified eIF4E/eIF4G inhibitor-1(4EGI-1) mimetic and their in vitro characterization as inhibitors of protein-protein interaction. J. Med. Chem., 2014, 57, 5094-5111.
19. Sekiyama, N.; Arthanari, H.; Papadopoulos, E.; Rodriguez-Mias, R.A.; Wagner, G.; Ler-Abraham, M. Molecular mechanism of the dual activity of 4EGI-1: Dissociating eIF4G from eIF4E but stabilizing the binding of unphosphorylated 4E-BP1. Proc. Natl. Acad. Sci. U.S.A. 2015, 112(30), E4036-E4045.
20. Papadopolulos, E.; Jenni, S.; Kabha, E.; Takrouri, K.J.; Yi, T.; Salvi, N.; Luna, R.E.; Gavathiotis, E.; Mahalingam, P.; Arthanari, H.; Rodriguez-Mias, R.; Yefidoff-Freedman, R.; Aktas, B.H.; Chorev, M.; Halperin, J.A.; Wagner, G. Structure of the eukaryotic translation initiation factor eIF4E in complex with 4EGI-1 reveals an allosteric mechanism for dissociating eIF4G. Proc. Natl. Acad. Sci. U.S.A., 2014, 111(31), E3187-E3195.
21. Lama, D.; Quah, S.T.; Verma, C.S.; Lakshminarayanan, R.; Beuerman, R.W.; Lane, D.P.; Brown, C.J. Rational optimization of conformational effects induced by hydrocarbon staples in peptides and their binding interfaces. Sci. Rep., 2013, 3, 3451.
22. Martinkovich, S.; Shah, D.; Planey, S.L.; Arnott, J.A. Selective estrogen receptor modulators: Tissue specificity and clinical utility. Clin. Interventions Aging, 2014, 9, 1437-1452.
23. Rodriguez, A.L.; Tamrazi, A.; Collins, M.L.; Katzenellenbogen, J.A. Design, synthesis, and in vitro biological evaluation of small molecule inhibitors of estrogen receptor alpha coactivator binding. J. Med. Chem., 2004, 47(3), 600-611.
24. Sun, A.; Moore, T.W.; Gunther, J.R.;Kim, M.S.; Rhoden, E.; Du, Y.; Fu, H.; Snyder, J.P.; Katzenellenbogen, J.A. Discovering small molecule estrogen receptor alpha/coactivator-binding inhibitors: High-throughput screening, ligand development, and models for enhanced potency. Chem. Med. Chem., 2011, 6(4), 654-666.
25. Leduc, A.M.; Trent, J.O.; Wittliff, J.L.; Bramlett, K.S.; Briggs, S.L.; Chirgadze, N.Y.; Wang, Y.; Burris, T.P.; Spatola, A.F. Helix-stabilized cyclic peptides as selective inhibitors of steroid receptor-coactivator interactions. Proc. Natl. Acad. Sci. U S A., 2003, 100(20), 11273-11278.
26. Phillips, C.; Roberts, L.R.; Schade, M.; Bazin, R.; Bent, A.; Davies, N.L.; Moore, R.; Pannifer, A.D.; Pickford, A.R.; Prior, S.H.; Read, C.M.; Scott, A.; Brown, D.G.; Xu, B.; Irving, S.L. Design and structure of stapled peptides binding to estrogen receptors. J. Am. Chem. Soc., 2011, 133, 9696-9699.
27. De Vries-van Leeuwen, I.J.; da Costa Pereira, D.; Flach, K.D.; Piersma, S.R.; Haase, C.; Bier, D.; Yalcin, Z.; Michalides, R.; Feenstra, K.A.; Jimez, C.R.; de Greef, T.F.A.; Brunsveld, L.; Ottmann, C.; Zwart, W.; de Boer, A.H. Interaction of 14-3-3 proteins with the estrogen recap tor alpha F domain provides a drug target interface. Proc. Natl. Acad. Sci. U.S.A., 2013, 110(22), 8894-8899.
28. de Boer, A.H.; de Vries-van Leeuwen, I.J. Fusicoccanes: Diterpenes with surprising biological functions. Trends Plant Sci .,2012, 17(6): 360-366.
29. Geistlinger, T.R.; McReynolds, A.C.; Guy, R.K. Ligandselective inhibition of the interaction of steroid receptor coactivators and estrogen receptor isoforms. Chem. Biol., 2004, 11, 273-281.
30. Galande, A.K.; Bramlett, K.S.; Burris, T.P.; Wittliff, J.L.; Spatold, A.F. Thioether side chain cyclization for helical peptide formation: Inhibitors of estrogen receptor-coactivator interactions. J. Pept. Res., 2004, 63, 297-302.
31. Li, L.Y. EZH2: Novel therapeutic target for human cancer. Biomedicine, 2014, 4(1), 1-6.
32. Qi, W.; Chan, H.M.; Teng, L.; Li, L.; Chuai, S.; Zhang, R.; Zeng, J.; Li, M.; Fan, H.; Lin, Y.; Gu, J.; Ardayfio, O.; Zhang, J.H.; Yan, X.; Fang, J.; Mi, Y.; Zhang, M.; Zhou, T.; Feng, G.; Chen, Z.; Li, G.; Yang, T.; Zhao, K.; Liu, X.; Yu, Z.; Lu, C.X.; Atadia, P.; Li, E. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc. Natl. Acad. Sci. U S A., 2012, 109(52), 21360-21365.
33. Kim, W.; Bird, G.H.; Neff, T.; Guo, G.; Kerenyi, M.A.; Walensky, L.D.; Orkin, S.H. Targeted disruption of the EZH2/EED complex inhibits EZH2-dependent cancer. Nat. Chem. Biol., 2013, 9(10), 643-650.
34. Tovar, C.; Rosinski, J.; Filipovic, Z.; Higgins, B.; Kolinsky, K.; Hilton, H.; Zhao, X.; Vu, B.T.; Qing, W.; Packman, K.; Myklebost, O.; Heimbrook, D.C.; Vassilev, L.T. Smallmolecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy. Proc. Natl. Acad. Sci. U.S.A, 2006, 10(6),1888-1893.
35. Zhang, Q.; Zeng, S.X.; Lu, H. Targeting p53-MDM2-MDMX loop for cancer therapy. Subcell Biochem., 2014, 85, 281-319.
36. Chang, Y.S.; Graves, B.; Guerlavais, V.; Tovar, C.; Packman, K.; To, K.H.; Olson, K.A.; Kesavan, K.; Gangurde, P.; Mukherjee, A.; Baker, T.; Darlak, K.; Elkin, C.; Filipovic, Z.; Qureshi, F.Z.; Cai, H.; Berry, P.; Feyfant, E.; Shi, X.E.; Horstick, J.; Annis, D.A.; Manning, A.M.; Fatouhi, N.; Nash, H.; Vassilev, L.T.; Sawyer, T.K. Stapled alphahelical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc. Natl. Acad. Sci. U S A., 2013, E3445-E3454.
37. Marine, J.C.; Lozano, G. Mdm2-mediated ubiquitylation: P53 and beyond. Cell Death Differ., 2010, 17, 93-102.
38. Vassilev LT. Small-molecule antagonists of p53-MDM2 binding. Cell Cycle, 2004, 3(4), 417-419.
39. Vassilev, L.T.; Vu, B.T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; Kammlott, U.; Lukacs, C.; Klein, C.; Fotouhi, N.; Liu, E.A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science, 2004, 303, 844-848.
40. Kojima, K.; Burks, J.K.; Arts, J.; Andreeff, M. The novel tryptamine derivative JNJ-26854165 induces wild-type p53-and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemia. Mol. Cancer Ther., 2010, 9(9), 2545-2557.
41. Yang, Y.; Ludwig, R.L; Jensen, J.P.; Pierre, S.A.; Medaglia, M.V.; Davydov, I.V.; Safiran, Y.J.; Oberoi, P.; Kenten, J.H.; Phillips, A.C.; Weissman, A.M.; Vousden, K.H. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell, 2005, 7(6), 547-559.
42. Dudgeon, D.D.; Shinde, S.; Hua, Y.; Shun, T.Y.; Lazo, J.S.; Strock, C.J.; Giuliano, K.A.; Taylor, D.L.; Johnston, P.A.; Johnston, P.A. Implementation of a 220,000-compound HCS campaign to identify disruptors of the interaction between p53 and hDM2 and characterization of the confirmed hits. J. Biomol. Screen., 2010, 15(7), 766-782.
43. Weber, L. Patented inhibitors of p53-Mdm2 interaction( 2006-2008). Exp, Opin. Ther. Pat., 2010, 20(2), 179-191.
44. Bernal, F.; Tyler, A.F.; Korsmeyer, S.J.; Walensky, L.D.; Verdine, G.L. Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide. J. Am.Chem.Soc., 2007, 129, 2456-2457.
45. Bernal, F.; Wade, M.; Godes, M. A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer Cell, 2010, 18(5), 411-422.
46. Li, K.; Li, Y.; Wu, W.; Gordon, W.R.; Chang, D.W.; Lu, M.; Scoggin, S.; Fu, T.; Vien, L.; Histen, G.; Zheng, J.; Martin-Hollister, R.; Duensing, T.; Singh, S.; Blacklow, S.C.; Yao, Z.; Aster, J.C.; Zhou, B.S. Modulation of Notch signaling by antibodies specific for the extracellular negative regulatory region of Notch3. J.Biol.Chem., 2008, 283(12), 8046-8054.
47. Ryeom, S. The cautionary tale of side effects of chronic Notch 1 inhibition. J.Clin.Invest., 2011, 121(2), 508-509.
48. Purow, B. Notch inhibition as a promising new approach to cancer therapy. Adv. Exp. Med. Biol., 2012, 727, 305-319
49. Kovall, R.A. More complicated than it looks: Assembly of Notch pathway transcription complexes. Oncogene, 2008, 27, 5099-5109.
50. Moellering, R.E.; Cornejo, M.; Davis, T.N.; Bianco, C.D.; Aster, J.C.; Blacklow, S.C.; Kung, A.L.; Gililand, D.G.; Verdine, G.L.; Bradner, J.E. Direct inhibition of the NOTCH transcription factor complex. Nature, 2009, 462(7270), 182-188.
51. Wu, Y.; Cain-Hom, C.; Choy, L.; Hagenbeek, T.J.; de Leon, G.P.; Chen, Y.; Finkle, D.; Venook, R.; Wu, X.; Ridgway, J.; Schahin-Reed, D.; Dow, G.J.; Shelton, A.; Stawicki, S.; Watts, R.J.; Zhang, J.; Choy, R.; Howard, P.; Kadyk, L.; Yan, M.; Zha, J.; Callahan, C.A.; Hymowitz, S.G.; Siebel, C.W. Therapeutic antibody targeting of individual Notch receptors. Nature, 2009, 464, 1052.
52. Zhou, B.S.; Peyton, M.; He, B.; Liu, C.; Girard, L.; Caudler, E.; Lo, Y.; Baribaud, F.; Mikami, I.; Requart, N.; Yang, G.; Li, Y.; Yao, W.; Vaddi, K.; Gazdar, A.F.; Friedman, S.M.; Jablons, D.M.; Newton, R.C.; Fridman, J.S.; Minna, J.D.; Scherle, P.A. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell, 2006, 10(1), 39-50.
53. Vaccari, T.; Lu, H.; Kanwar, R.; Fortini, M.E.; Bilder, D. Endosomal entry regulates Notch receptor activation in Drosophila melanogaster. J. Cell. Biol., 2008, 180(4), 755-762.
54. Sweeney, C.; Morrow, D.; Birney, Y.A.; Coyle, S.; Hennessy, C.; Scheller, A.; Cummins, P.M.; Walls, D.; Redmond, E.M.; Cahil, P.A. Notch 1 and 3 receptor signaling modulates vascular smooth cell growth, apoptosis, and migration via a CBF-1/RBP-JK dependent pathway. FASEB J., 2004, 18(12), 1421-1423.
55. Hao, Y.; Zhao, S.; Wang, Z. Targeting the protein-protein interaction between IRS1 and mutant p110alpha for cancer therapy. Toxicol. Pathol., 2014; 42(1), 140-147.
56. Hao, Y.; Wang, C.; Cao, B.; Hirsch, B.M.; Song, J.; Markowitz, S.D.; Ewing, R.M.; Sedwick, D.; Liu, L.; Zheng, W.; Wang, Z. Gain of interaction with IRS1 by p110alpha helical domain mutants is crucial for their oncogenic functions. Cancer Cell, 2013, 23(5), 583-593.
57. LaCasse, E.C.; Mahoney, D.J.; Cheung, H.H.; Plenchette, S.; Baird, S.; Korneluk, R.G. IAP-targeted therapies for cancer. Oncogene, 2008, 27, 6253-6275.
58. Verdecia, M.A.; Huang, H.K.; Dutil, E.; Kaiser, D.A.; Hunter, T.; Noel, J.P. Structure of the human anti-apoptotic protein surviving reveals a dimeric arrangement. Nat. Struc. Mol. Biol., 2000, 7, 602-608.
59. Groner, B.; Weiss, A. Targeting survivin in cancer: Novel drug development approaches. Bio Drugs, 2014, 28, 27-39.
60. Chen, J.; Jin, S.; Tahir, S.K.; Zhang, H.; Liu, X.; Sarthy, A.V.; McGonigal, T.P.; Liu, Z.; Rosenberg, S.H.; Ng, S.C. Survivin enhances Aurora-B kinase activity and localizes Aurora-B in human cells. J. Biol. Chem., 2003, 278(1), 486-490.
61. Lens, S.M.; Medema, R.H. The surviving/Aurora B complex: Its role in coordinating tension and attachment. Cell Cycle, 2003, 2(6), 507-510.
62. McKenzie, J.A.; Grossman, D. Role of the apoptotic and mitotic regulator survivin in melanoma. Anticancer Res., 2012, 32, 397-404.
63. Berezov, A.; Wang, Q.; Murali, R.; Greene, M.I. Method of treating cancer using a survivin inhibitor. U.S.Patent 8,710,068 B2, April 29, 2014.
64. Ewing, T.J.; Makino, S.; Skillman, A.G.; Kuntz, I.D. DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases. J. Comput. Aided Mol. Des., 2001, 15, 411-428.
65. Shi, Z.; Wales, T.E.; Elkin, C.; Kawahata, N.; Engen, J.R.; Annis, D.A. Hydrogen exchange-mass spectrometry measures stapled peptide conformational dynamics and predicts pharmacokinetic properties. Anal. Chem., 2013, 85(23), 1-8.